Medtronic’s Portfolio Management Unlikely To Be A ‘Magic Bullet,’ Says Needham
Needham published a report that pointed to previous comments from Medtronic plc's (NYSE: MDT) management that indicate the potential for changes in the coming year, with a spinoff of a large business considered an option.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Medtronic’s US Trial Of GI Genius Endoscopy Module Reduces Missed Colorectal Polyps By 50%
Medtronic plc (NYSE:MDT) announced final findings from a study that confirmed the effectiveness of the GI Genius intelligent endoscopy module. GI…
Rockley Photonics Holdings And Medtronic To Collaborate On Bioptx Biomarker Sensing Platform
Rockley and Medtronic to enter development partnership involving newly announced Bioptx™ biomarker sensing platform
Companies partner to jointly develop regulated wearable devices for proactive and continuous
FDA Approves Medtronic’s Recharge-Free Sacral Nerve Stimulation Therapy For Bladder, Bowel Control
The FDA has approved Medtronic plc's (NYSE:
Needham Maintains Buy on Medtronic, Lowers Price Target to $124
Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and lowers the price target from $128 to $124.
Medtronic Receives FDA approval For InterStim X system
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the
